Hepatitis delta virus whole genotype dual fluorescent quantitative PCR (polymerase chain reaction) detection reagent

By designing specific primers and probes combined with dual fluorescence quantitative PCR technology, the problem that the existing technology cannot detect the entire genotype of the hepatitis D virus is solved, and the comprehensive detection of eight genotypes is achieved, with high sensitivity and strong specificity It is suitable for large-scale clinical use, helping to improve the accuracy of patient data and prevention and control effects.

CN118932112APending Publication Date: 2024-11-12KUNMING UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411010160.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing technology cannot effectively detect the entire genotype of hepatitis D virus, resulting in inaccurate detection results and the inability to quickly and sensitively identify type III viruses, resulting in underestimation of patient data and severe prevention and control situation.

Method used

Design specific primers and probes for hepatitis D virus type I to VIII, combined with dual fluorescence quantitative PCR technology to achieve comprehensive detection of eight genotypes, using 42℃ reverse transcription, 95℃ prededenatation and 62℃ The reaction procedure for annealing extension is determined by detecting the Cq value through fluorescence signal.

Benefits of technology

The comprehensive detection of eight genotypes of hepatitis D virus has been achieved, with high sensitivity, strong specificity and good repetition, which can be diagnosed quickly and accurately, reduces costs, and is suitable for large-scale clinical use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932112A_ABST
    Figure CN118932112A_ABST
Patent Text Reader

Abstract

The invention discloses a hepatitis D virus whole genotype dual fluorescent quantitative PCR (Polymerase Chain Reaction) detection reagent. The detection reagent comprises specific primers and probes aiming at hepatitis D viruses I-VIII, wherein the specific primers for the hepatitis D virus type I, the hepatitis D virus type II, the hepatitis D virus type IV, the hepatitis D virus type II, the hepatitis D virus type VIII and the hepatitis D virus type VIII are CGGYAATGGCGAATGGGAC and GGGTCGGCATGGTCGC, and the probe is CTCCTTCGGATGCCCAGGTCGG; the specific primers aiming at the hepatitis D virus type III are respectively GTTCGGAAAAGGGGGACC and GGATGACGAAAGAGAAAGAAG, and the probe is TGTGAACCCAATGGACGGCC, and the specific primers aiming at the hepatitis D virus type III are respectively GTTCGGGAAAAGGGGGGACC and GGATGACGGGGACGGCCC; the detection reagent provided by the invention has the characteristics of strong specificity, good stability and reproducibility, high sensitivity and the like, and has great value in clinical rapid diagnosis and symptomatic medication.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of hepatitis D virus detection, and in particular relates to a hepatitis D virus full genotype dual fluorescence quantitative PCR detection reagent. Background Art

[0002] Hepatitis delta virus (HDV) combined with hepatitis B virus (HBV) infection can cause the most severe viral hepatitis and greatly accelerate the progression of liver disease. Studies have found that patients infected with HDV generally develop cirrhosis and liver cancer within 5-10 years. In comparison, clinically, patients with HBV infection alone and HCV infection generally take about 15-25 years to develop cirrhosis and liver cancer.

[0003] There are 8 genotypes of HDV, among which type III is distantly related to other genotypes. Studies have found that clinically, the genotype of HDV is associated with clinical symptoms, mainly manifested in that type III is prone to cause fulminant hepatitis, types II and IV have milder clinical symptoms, and types I and V have a high mortality rate.

[0004] Hepatitis D virus is widely spread around the world, and it is estimated that about 15 million people are infected with HDV worldwide. According to model predictions, China is the country with the largest number of HDV infections. International guidelines recommend clinical screening for HDV in chronic HBV patients, but on the one hand, HDV RNA is very prone to mutation, resulting in no standardized detection technology for clinical use. On the other hand, the international community recommends the use of enzyme-linked immunosorbent assay for antibody detection as a means of clinically detecting HDV antibodies, but the quality of the kits currently used on the market is uneven, often leading to inaccurate results. Therefore, the detection of HDV RNA in the blood is currently the "gold standard" for confirming HDV infection. Furthermore, most of the fluorescence quantitative PCR detection methods currently developed are for HDV type I, and are unable to fully detect the eight genotypes. These reasons have, to a certain extent, led to a lack of data on the prevalence of HDV in my country, and the number of infected people has been seriously underestimated, which has indirectly led to a very serious situation for the prevention and control of HDV in my country.

[0005] Traditional serological detection methods have low sensitivity, long time consumption, high cost, and cannot distinguish genotypes, especially cannot quickly and sensitively identify hepatitis D virus type III, which is prone to cause fulminant hepatitis. Therefore, traditional methods are not suitable for large-scale clinical use. Multiplex fluorescence quantitative PCR detection technology can well circumvent the weaknesses of serological detection. It has high sensitivity, strong specificity, good repeatability, simple operation, can quickly obtain results, and can achieve comprehensive detection of HDV genotypes, facilitate symptomatic medication, and improve clinical cure effects. At the same time, it helps researchers accurately grasp the prevalence of HDV in my country and provide a strong basis for the prevention and control of HDV in my country. Summary of the invention

[0006] In view of the shortcomings of existing hepatitis D virus detection, the present invention provides a detection reagent for comprehensively detecting eight genotypes of hepatitis D virus using dual real-time fluorescent quantitative PCR, so as to solve the problem that the existing technology is difficult to fully detect all genotypes of hepatitis D virus.

[0007] To achieve the above purpose, the present invention designs specific primers and probes for highly conserved sequences of hepatitis D virus types Ⅰ to Ⅷ, wherein the specific primers for hepatitis D virus types Ⅰ, Ⅱ, Ⅳ to Ⅷ are HDV124~8F: CGGY AATGGCGAATGGGAC, HDV124~8R: GGGTCGGCATGGCATCTC, and the probe is HDV124~8P: CTCCTTCGGATGCCCAGGTCGG;

[0008] The specific primers for hepatitis D virus type III are HDV3F: GTTCGGGAAAAGGGGGACTC and HD V3R: GGATGACGACGAAAGAGAAAGAAG, and the probe is HDG3P: TGTGAACCCAATGGACG GCCC.

[0009] The detection reagent of the present invention also includes other conventional reagents used for dual fluorescence quantitative PCR detection.

[0010] The method of using the above dual fluorescence quantitative PCR detection reagent is as follows:

[0011] 1. Collect whole blood samples from clinical patients with positive hepatitis B virus in the liver disease clinic in anticoagulant tubes, check and record the patient information during sampling, register it, store it at low temperature during transportation, and store it at -80℃ later;

[0012] 2. Use Tiangen Virus Genomic DNA / RNA Extraction Kit to extract hepatitis D virus genomic RNA from blood;

[0013] 3. Using the RNA extracted in step 2 as a template, specific primers and probes for eight genotypes of hepatitis D virus were used to perform multiplex fluorescence quantitative PCR detection according to the reaction procedure and reaction system, and the results were determined according to the Cq value; the reaction procedure was reverse transcription at 42°C for 5 min, pre-denaturation at 95°C for 30 sec, denaturation at 95°C for 5 sec, annealing and extension at 62°C for 30 sec, and 39 cycles; the fluorescence signal was collected during the annealing and extension stage of each cycle.

[0014] The interpretation of the test results includes the following: (1) The amplification curve is a standard "S" shape, and the curve should be smooth without obvious jagged edges or plateaus; the threshold line should be located in the exponential growth phase of the amplification curve and should be in the middle of the curve, not too high or too low; there is no Cq value for the negative control group and the no-template control group; the repeatability between duplicate wells is good. If it does not meet the requirements, multiplex fluorescence quantitative PCR testing must be performed again, or nucleic acid must be re-extracted for multiplex fluorescence quantitative PCR testing; (2) The pathogen Ct value ≤35.0 is positive.

[0015] Compared with previous detection methods, the present invention has the following advantages:

[0016] The present invention can achieve comprehensive detection of eight genotypes of hepatitis D virus in one PCR system, making up for the deficiency that only hepatitis D virus type I can be detected internationally, covering a wider range of genotypes, and is more cost-effective and rapid than the fluorescent quantitative method using eight sets of primers and probes;

[0017] The detection method of the present invention does not amplify hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, hepatitis E virus (HEV) DNA and dengue virus (DENV) RNA appearing in clinical samples, indicating that the method has strong specificity; the detection sensitivity of the method can reach 100 copies / μL, indicating that the method has high sensitivity; the inter-batch and intra-batch repeatability of the method is evaluated and it is found that the inter-batch and intra-batch coefficients of variation (CV%) of the method are both less than 2.0%, indicating that the method has good repeatability and reproducibility.

[0018] The detection reagent of the present invention has the characteristics of high sensitivity, strong specificity, good repeatability and reproducibility, rapid detection, low cost, etc., and is of great value for rapid clinical diagnosis and symptomatic medication. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a schematic diagram of sequencing results of positive standards of highly conserved sequences of hepatitis D virus type I, II, IV-VIII of the present invention;

[0020] Figure 2 This is a schematic diagram of sequencing results of a positive standard sample of the highly conserved sequence of hepatitis D virus type III of the present invention;

[0021] Figure 3 It is a schematic diagram of amplification curves of different primer concentrations for hepatitis D virus type I, type II, and type IV to VIII of the present invention;

[0022] Figure 4 It is a schematic diagram of the amplification curve of hepatitis D virus type III with different primer concentrations of the present invention;

[0023] Figure 5 Schematic diagram of amplification curves of different probe concentrations for hepatitis D virus type I, II, and IV to VIII of the present invention;

[0024] Figure 6 Schematic diagram of amplification curves of hepatitis D virus type III at different probe concentrations according to the present invention;

[0025] Figure 7 It is the specific experimental result of dual fluorescence quantitative PCR;

[0026] Figure 8 This is a schematic diagram of the linear interval verification of multiplex fluorescence quantitative PCR for hepatitis D virus (HDV) type Ⅰ, type Ⅱ, and type Ⅳ to Ⅷ;

[0027] Fig. 9 This is a schematic diagram of the linear interval verification of hepatitis D virus (HDV) type III dual fluorescence quantitative PCR;

[0028] Fig.10 This is a schematic diagram of the standard curve of dual fluorescence quantitative PCR for hepatitis D virus (HDV) type Ⅰ, type Ⅱ, type Ⅳ to Ⅷ;

[0029] Fig.11 This is a schematic diagram of the standard curve of hepatitis D virus (HDV) type III dual fluorescence quantitative PCR. DETAILED DESCRIPTION

[0030] The specific implementation of the present invention is further described below in conjunction with the examples, but the implementation and protection of the present invention are not limited thereto. It should be noted that if there are processes that are not particularly described in detail below, they can be implemented or understood by those skilled in the art with reference to the prior art; the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0031] Example 1: Design of specific primers and probes

[0032] 1. Download eight genotype reference sequences of hepatitis D virus from NCBI (https: / / www.ncbi.nlm.nih.gov / );

[0033] 2. Use Mega 11 software to align the nucleotide sequences, and use Primer Select software to design primers and probes for hepatitis D virus types Ⅰ, Ⅱ to Ⅷ, and Ⅲ;

[0034] 3. BLAST evaluation of primers and probes: The nucleotide sequences of the primers and probes that were initially designed were compared again using the BLAST search function on the NCBI website to select primers and probe sequences with high specificity. The primers and probes were synthesized by Sangon Biotech Co., Ltd.

[0035] The nucleotide sequences of specific primers and probes targeting eight genotypes of hepatitis D virus (HDV-Ⅰ, HDV-Ⅱ, HDV-Ⅲ, HDV-Ⅳ, HDV-Ⅴ, HDV-Ⅵ, HDV-Ⅶ, HDV-Ⅷ) are shown in the following table:

[0036]

[0037] Example 2: Establishment of dual fluorescence quantitative PCR method

[0038] 1. Construction and verification of plasmid

[0039] The highly conserved nucleotide sequence of hepatitis D virus type I, II, IV-VIII (SEQ ID NO: 1) was connected to the pUC57 vector, and the highly conserved nucleotide sequence of hepatitis D virus type III (SEQ ID NO: 2) was connected to the pUC57 vector to synthesize the hepatitis D virus positive standards G4aTW and G3BR. The plasmid construction was completed by Sangon Biotech Co., Ltd. After activating the synthesized plasmid glycerol bacteria, the plasmid was extracted and sent for testing. The concentration was measured by an ultraviolet spectrophotometer, and the copy number of the plasmid was calculated according to the length and concentration of each plasmid. The calculation formula is as follows:

[0040]

[0041] The copy number results are shown in the following table:

[0042] Plasmid name Fragment size (bp) Plasmid concentration (ng / μL) Copy number (copies / μL) GqV 254 691.7 2.1293E+11 G3BR 233 792.05 2.45561E+11

[0043] The sequencing results are as follows Figure 1 , Figure 2 As shown, according to the sequencing results, it was shown that both plasmid standards were successfully constructed.

[0044] 2. Optimization of dual fluorescence quantitative reaction system

[0045] (1) Optimization of single-plex fluorescence quantitative PCR reaction system

[0046] The above plasmid standard was diluted tenfold (10 10 -10 1), according to the initial reaction system and reaction conditions recommended in the instructions of the one-step kit (Ag11713) of Acryl, 10 10 ~10 1 Real-time fluorescence quantitative PCR was performed with plasmid standards of 100 copies / μL. According to the experimental results, positive standards with a concentration gradient of Cq values ​​between 15 and 25 were selected. The final concentrations of upstream and downstream primers in the reaction system were 200nM, 300nM, and 400nM, respectively. The "matrix method" was used to optimize the primer concentrations. According to the principles of minimum Cq value, maximum fluorescence intensity, and minimum primer dimers, the optimal concentrations of upstream and downstream primers in the reaction system were finally determined to be 200nM. The results are shown in the figure. Figure 3 , Figure 4 As shown; Similarly, positive standards with a concentration gradient of Cq values ​​between 15 and 25 were selected to optimize the probe concentration according to the final concentration of the probe in the reaction system of 100nM, 150nM, 200nM, and 250nM, and finally the final concentration of the probe in the single-plex reaction system was determined to be 200nM; the results are shown Figure 5 , Figure 6 As shown;

[0047] Optimization of single-plex fluorescence quantitative PCR annealing temperature: select 10 7 -10 2 The plasmid with 100 copies / μL was annealed at 56°C, 58°C, 60°C, 62°C, and 64°C according to the optimized reaction system. The amplification efficiency and R 2 , slope, etc., and finally 60°C was selected as the optimal annealing temperature for the primer-probe combination of hepatitis D virus type III, and 62°C was the optimal annealing temperature for the primer-probe combination of hepatitis D virus types I, II, IV to VIII;

[0048] (2) Optimization of dual fluorescence quantitative PCR reaction system

[0049] The final concentrations of primers and probes in the single-plex fluorescence quantitative PCR reaction system were used as the final concentrations of the dual fluorescence quantitative PCR reaction system, i.e., the concentrations of upstream and downstream primers were 200 nM, and the concentration of probes was 200 nM;

[0050] Optimization of annealing temperature for dual fluorescence quantitative PCR

[0051] Use 10 10 -10 1 The concentration gradient plasmid standard was set at 60℃ and 62℃ respectively according to the optimized reaction system. The annealing temperature of dual fluorescence quantitative PCR was optimized, and the amplification efficiency and R were calculated according to the Cq value. 2 , slope, etc. The results are shown in the following table. Finally, the annealing temperature of the dual fluorescence quantitative PCR reaction was determined to be 62°C;

[0052]

[0053] The final double fluorescence quantitative PCR reaction system was determined as follows: 2×One Step RT-qPCR BufferⅡ(probe)10μL, pro tTaq HSDNAPolymerase(5U / μL)0.4μL, Evo M-MLV RTase Enzyme MixⅡ0.4μL, Primer F(10μM)0.4μL, Primer R(10μM)0.4μL, probe 0.8μL, template 1μL, and water was added to make up to 20μL;

[0054] The final double fluorescence quantitative PCR reaction program was determined as follows: reverse transcription at 42°C for 5 min; pre-denaturation at 95°C for 5 sec; denaturation at 95°C for 30 sec, annealing and extension at 62°C for 30 sec, for 39 cycles.

[0055] Example 3: Evaluation of specificity, sensitivity and repeatability of fluorescent quantitative PCR using primers and probes of the present invention

[0056] 1. Evaluation of specificity of dual fluorescence quantitative PCR

[0057] DNA / RNA of hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV) and dengue virus (DENV), which also cause viral hepatitis in clinic, were selected. 7 The plasmid standard with 1000 copies / μL was used as the detection object, and sterile water was used as the blank control. The dual fluorescence quantitative PCR specific detection was performed according to the reaction system annealing temperature optimized in Example 2;

[0058] The results are as follows Figure 7 As shown, except for the hepatitis D virus, the others were not amplified, indicating that the method has good specificity.

[0059] 2. Evaluation of sensitivity of dual fluorescence quantitative PCR

[0060] Take 10 7 ~10 2 The positive plasmid standard was used as a template and sterile water was used as a negative control. The sensitivity of the present invention was evaluated according to the optimized reaction system and reaction procedure.

[0061] The results are as follows Figure 8 , Fig. 9 As shown, the amplification curves are 10 from left to right. 7 copies / μL, 10 6 copies / μL, 10 5copies / μL, 10 4 copies / μL, 10 3 copies / μL, 10 2 The results showed that the minimum detection limit of the detection system of the present invention for hepatitis D virus was 100 copies / μL.

[0062] A standard curve was established with the logarithmic value of template concentration as the horizontal axis and the number of cycles as the vertical axis, such as Fig.10 , Fig.11 As shown in the figure, the standard curve constructed based on the highly conserved sequences of hepatitis D virus (HDV) type I, II, IV-VIII has an amplification efficiency of 94% and R 2 The amplification efficiency of the standard curve constructed based on the highly conservative sequence of hepatitis D virus type III was 90.6%, and the R 2 It is 0.9992, indicating a good linear relationship.

[0063] 3. Evaluation of repeatability of dual fluorescence quantitative PCR

[0064] In order to verify the repeatability of the multiplex qPCR detection method, a concentration gradient of 10 6 -10 1 The plasmid standard with 1000 copies / μL was used as the positive template. The intra-batch repeat experiment was performed with three replicates for each template. For three consecutive days, the inter-batch repeat experiment was performed with three replicates for each template. The intra-batch and inter-batch coefficients of variation (CV%) were calculated based on the Cq values ​​to evaluate the repeatability and reproducibility of the method.

[0065]

[0066] The results of the repeatability test are shown in the following table. The results show that the coefficient of variation CV < 2%, indicating that the repeatability and reproducibility of the present invention are

[0067]

[0068] Good sex;

[0070] Example 4: Dual fluorescence quantitative PCR detection of clinical samples

[0071] 1. Sample source

[0072] Collect 1 mL of whole blood from 50 clinical patients with positive hepatitis B virus into sterile EP tubes, carefully check the patient information, mark them, register them, store them at 4°C during transportation, and store the samples at -80°C until nucleic acid extraction;

[0073] 2. Nucleic Acid Extraction

[0074] RNA was extracted using the Tiangen virus genome DNA / RNA extraction kit. The specific steps are as follows:

[0075] a. Preparation before the experiment: before using the Tiangen virus genomic DNA / RNA extraction kit, add 70 mL and 17 mL of anhydrous ethanol to the rinse solution PW and buffer GD respectively;

[0076] b. Sample aliquoting: aliquot 200 μL of blood into a new EP tube and add 20 μL of Protein K;

[0077] c. Add 200 μL of the prepared Carrier RNA working solution to the EP tube, vortex and shake, place in a 56°C water bath for 15 minutes, centrifuge briefly, add 250 μL of anhydrous ethanol, shake for 15 seconds, and let stand for 5 minutes. At this time, flocculent precipitation will be produced;

[0078] d. Transfer the flocculent precipitate and solution mixture to the adsorption column, centrifuge at 8000rpm for 1min, discard the waste liquid, add 500μL buffer GD, centrifuge at 8000rpm for 1min, discard the waste liquid; place the adsorption column in the collection tube

[0079] e. Add 600 μL of rinse solution PW, let stand for 2 minutes, centrifuge at 8000 rpm for 1 minute, and discard the waste liquid. Repeat this step twice;

[0080] f. Add 500 μL of anhydrous ethanol, centrifuge at 8000 rpm for 1 min, discard the waste liquid, and then centrifuge at 12000 rpm for 3 min, and discard the waste liquid;

[0081] h. Place the adsorption column in a new enzyme-free centrifuge tube, add 45 μL RNase-Free ddH2O in the middle of the adsorption membrane, place it at room temperature for 5 minutes, centrifuge it at 12000 rpm for 3 minutes, collect the nucleic acid solution at the bottom of the tube, divide it into smaller pieces according to the experimental situation and store it at -20℃ for later use.

[0082] 3. Dual qPCR detection

[0083] The nucleic acid extracted in step "2" was used as a template and detected using a Biori CFX-96 real-time fluorescence quantitative PCR instrument. The amplification reaction procedure was: reverse transcription at 42°C for 5 min; pre-denaturation at 95°C for 5 sec; denaturation at 95°C for 30 sec, annealing and extension at 62°C for 30 sec, 39 cycles; fluorescence signals were collected during the annealing and extension phase of each cycle; the reaction system was optimized with the multiplex qPCR reaction system in step 2 of Example 2;

[0084] The present invention was used to detect 50 extracted HBV positive samples, and the Cq values ​​were all greater than 35, indicating that the tested samples were all HDV negative.

[0085] At the same time, ELISA antibody detection kit was used as a control to detect IgM and IgG antibodies in the samples. All 50 HBV-positive samples tested were HDV-negative, which was consistent with the detection results of the present invention.

Claims

1. A dual fluorescence quantitative PCR detection reagent for all genotypes of hepatitis D virus, characterized in that: Including specific primers and probes for hepatitis D virus types Ⅰ to Ⅷ; The specific primers for hepatitis D virus types Ⅰ, Ⅱ, Ⅳ to Ⅷ are CGGYAATGGCGAATGGGAC and GGGTCGGCATGGCATCTC, and the probe is CTCCTTCGGATGCCCAGGTCGG; The specific primers for hepatitis D virus type III are GTTCGGGAAAAGGGGGACTC and GGATGACGACGAAAGAGAAAGAAG, and the probe is TGTGAACCCAATGGACGGCCC.